INSIGHT. What trends will shape life science and digital health in the year ahead? Below, we share our insights. 1. Precision medicine reaches everyday clinical practice Personalised treatment has long been a promise, and is now becoming reality. In Sweden, Genomic Medicine Sweden has received SEK 80 million in government
NEWS. Andreas Lindblom, co-founder and Managing Partner at Sciety, features in the latest episode of BioStock’s podcast Health and Wealth – a podcast about investing in life science. In the episode, Andreas shares the strategy that has kept Sciety on a steady growth trajectory through ten years of investing in
PRESS RELEASE. Sciety has led a SEK 87 million financing round for Neogap Therapeutics, a Swedish clinical-stage biotech company developing personalised immunotherapy for cancer. The capital will be used to advance the company’s ongoing Phase I/II clinical trial and build the clinical data required for the next stage of development.
INSIGHT. Nerve pain has long been considered difficult to treat. Current medications often provide inadequate relief and are associated with side effects such as fatigue, dizziness, and risk of addiction. At the same time, the patient population is growing rapidly, driven primarily by diabetes-related nerve damage (neuropathy), which affects up
INSIGHT. Mental health is one of the greatest health challenges of our time. Nearly one billion people worldwide experience mental health conditions each year, yet fewer than one in ten receive adequate treatment. In Sweden, mental health issues is the leading cause of long-term sick leave and accounts for 42
PRESS RELEASE. Sciety’s portfolio company PeptiSystems has secured an investment from Rubicon Healthcare Partners, making Rubicon a new shareholder in the company. The investment strengthens PeptiSystems’ position in a rapidly growing market segment and marks the next step in its international expansion. PeptiSystems develops and sells synthesis instruments that streamline
Sciety is a capital partner specialising in life science and healthcare, offering services in capital raising and related areas. Sciety may currently have, may previously have had or may in the future be engaged by companies mentioned in our communications or operating in the sectors described, and may hold ownership interests in such companies. Sciety receives remuneration for its services, including commissions in connection to capital raises. Our communication is intended for informational purposes only and does not constitute personal investment advice. We do not guarantee the accuracy, completeness or timeliness of the information provided. Investment decisions should not be based solely on this communication.